As a member of the TarGeT Collaborative, we are pleased to share a significant milestone in the progress of the TarGeT trial.
Intended to open in 2026, children across Australia and New Zealand who are diagnosed with high-grade brain cancers will have the opportunity to take part in this world-leading international study. TarGeT is an innovative umbrella trial that tests multiple targeted treatments at the same time and uses precision medicine to match therapies to shared genetic features. Its adaptive design allows trial teams to refine treatment arms in real time, helping researchers learn more quickly which approaches show the most promise.
With the support of ANZCHOG, the trial is now preparing to open across hospital sites in both countries. This will expand access to cutting-edge research for families and ensure children can participate regardless of their specific tumour type.
As Professor Nick Gottardo notes, “We urgently need trials like this so we can move quickly to understand which therapies might work for these very hard to treat cancers.”
We are deeply grateful to our funders and partners whose ongoing commitment is making this work possible. Together, we are helping to accelerate progress for children facing some of the most challenging cancer diagnoses.
